At the molecular level, PPARβ appears to regulate myostatin and PPARγ levels in muscle and bone, thereby providing potential new mechanisms to explain bone fragility related to metabolic syndromes and potentially identifying new molecular targets for the treatment of muscle and bone fragility in diabetes. Here, MSTN is linked to diabetes mellitus.